SG11201808750PA - T cell receptors - Google Patents
T cell receptorsInfo
- Publication number
- SG11201808750PA SG11201808750PA SG11201808750PA SG11201808750PA SG11201808750PA SG 11201808750P A SG11201808750P A SG 11201808750PA SG 11201808750P A SG11201808750P A SG 11201808750PA SG 11201808750P A SG11201808750P A SG 11201808750PA SG 11201808750P A SG11201808750P A SG 11201808750PA
- Authority
- SG
- Singapore
- Prior art keywords
- tcrs
- international
- park
- abingdon
- pct
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 9
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111110111 0 HEIN HOF 0 11I010 110 111111010111 001110111 III International Bureau .. .... ..Yejd (10) International Publication Number ..... .....1 (43) International Publication Date WO 2017/174823 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: C07K 14/725 (2006.01) CO7K 14/47 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: PCT/EP2017/058578 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: 10 April 2017 (10.04.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1606156.6 8 April 2016 (08.04.2016) GB kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: ADAPTIMMUNE LIMITED [GB/GB]; 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). (72) Inventors: TRIBBLE, Nicholas; c/o Adaptimmune Lim- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, ited, 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). LAWRANCE, William; c/o Adaptim- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). mune Limited, 101 Park Drive, Milton Park, Abingdon Ox- Published: fordshire OX14 4RY (GB). BAGG, Eleanor; c/o Adaptim- mune Limited, 101 Park Drive, Milton Park, Abingdon Ox- - with international search report (Art. 21(3)) — fordshire OX14 4RY (GB). — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of = (74) Agent: BIRTLE, Zoe; 30 Carlton Crescent, Southampton Hampshire S015 2EW (GB). amendments (Rule 48.2(h)) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (81) = = = = = = = = = = = 1-1 M ei cc ii- IN ,-1 (54) Title: T CELL RECEPTORS C 1-1 (57) : The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVY - el DGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein. The TCRs of the invention demonstrate excellent specificity pro - en) files for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells har - 7 19 bouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the 5 invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606156 | 2016-04-08 | ||
| PCT/EP2017/058578 WO2017174823A1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808750PA true SG11201808750PA (en) | 2018-11-29 |
Family
ID=58536983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808750PA SG11201808750PA (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190144521A1 (en) |
| EP (2) | EP3925972A1 (en) |
| JP (2) | JP7204484B2 (en) |
| KR (1) | KR20190065189A (en) |
| CN (2) | CN109476724B (en) |
| AU (2) | AU2017248121B2 (en) |
| BR (1) | BR112018070637A2 (en) |
| CA (1) | CA3020555A1 (en) |
| ES (1) | ES2788188T5 (en) |
| IL (1) | IL262124A (en) |
| MX (1) | MX2018012268A (en) |
| RU (1) | RU2018138837A (en) |
| SG (1) | SG11201808750PA (en) |
| WO (1) | WO2017174823A1 (en) |
| ZA (1) | ZA201806862B (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211753T1 (en) | 2014-12-23 | 2022-04-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| DK3440102T3 (en) | 2016-04-08 | 2024-07-22 | Adaptimmune Ltd | T cell receptors |
| PL3440106T3 (en) | 2016-04-08 | 2022-01-31 | Adaptimmune Limited | T cell receptors |
| AU2017248121B2 (en) * | 2016-04-08 | 2022-07-21 | Adaptimmune Limited | T cell receptors |
| CA3078472A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
| EP3747456A4 (en) * | 2018-01-31 | 2021-12-01 | Tohoku University | Method for regulating antigen-specific mhc expression |
| CN112236447B (en) * | 2018-04-19 | 2023-10-20 | 得克萨斯州大学系统董事会 | T cell receptor with MAGE-B2 specificity and uses thereof |
| CN110172091B (en) * | 2019-04-28 | 2020-04-03 | 天津亨佳生物科技发展有限公司 | Specific T cell receptor aiming at EGFR L858R gene mutation and application thereof |
| EP3986938A4 (en) * | 2019-06-18 | 2023-06-28 | Regeneron Pharmaceuticals, Inc. | Mage-a4 t cell receptors and methods of use thereof |
| KR20220032568A (en) | 2019-06-25 | 2022-03-15 | 길리애드 사이언시즈, 인코포레이티드 | FLT3L-FC fusion protein and methods of use |
| CA3150818A1 (en) | 2019-08-13 | 2021-02-18 | King's College London | Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily |
| US20210048442A1 (en) | 2019-08-13 | 2021-02-18 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:mhc binding polypeptides |
| PE20231067A1 (en) | 2020-02-14 | 2023-07-17 | Jounce Therapeutics Inc | ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND THEIR USES |
| CN111647069B (en) * | 2020-06-17 | 2022-06-21 | 深圳豪石生物科技有限公司 | Improved TCR and application thereof |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| WO2022140321A2 (en) * | 2020-12-22 | 2022-06-30 | Amgen Inc. | Mage-b2-specific t-cell receptors |
| MX2023010541A (en) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Mage-a4 peptide-mhc antigen binding proteins. |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| MX2024005066A (en) | 2021-10-29 | 2024-05-24 | Gilead Sciences Inc | Cd73 compounds. |
| CN118488948A (en) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | IKAROS zinc finger family degradation agent and application thereof |
| CN118488946A (en) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | IKAROS zinc finger family degradation agent and application thereof |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| EP4245756B1 (en) | 2022-03-17 | 2024-10-09 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN116836261A (en) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术（广东）有限公司 | High-affinity TCR (TCR) for recognizing MAGE-A4 antigen, and sequence and application thereof |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117106060A (en) * | 2022-05-17 | 2023-11-24 | 香雪生命科学技术（广东）有限公司 | High-affinity T cell receptor for recognizing MAGE and application thereof |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596536B1 (en) * | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| WO2000020445A2 (en) | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| US6407063B1 (en) | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
| US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| ES2239246T3 (en) | 2001-08-31 | 2005-09-16 | Avidex Limited | SOLUBLE RECEIVER OF CELLS T. |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US10024868B2 (en) | 2009-06-09 | 2018-07-17 | Vaxon Biotech | Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy |
| PT2618835T (en) | 2010-09-20 | 2017-08-08 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | Antigen-specific t cell receptors and t cell epitopes |
| BR112014008691A2 (en) * | 2011-10-14 | 2017-06-13 | Teva Pharmaceuticals Australia Pty Ltd | antibodies to cd1d |
| AU2014278323B2 (en) * | 2013-06-10 | 2020-05-28 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| JP6255360B2 (en) | 2015-03-04 | 2017-12-27 | ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ | Identification, optimization and use of immunotherapy for shared HLA-B * 0702 epitopes |
| EP4023668A1 (en) | 2016-04-08 | 2022-07-06 | Immunocore Limited | T cell receptors |
| AU2017248121B2 (en) * | 2016-04-08 | 2022-07-21 | Adaptimmune Limited | T cell receptors |
| PL3440106T3 (en) | 2016-04-08 | 2022-01-31 | Adaptimmune Limited | T cell receptors |
| DK3440102T3 (en) | 2016-04-08 | 2024-07-22 | Adaptimmune Ltd | T cell receptors |
-
2017
- 2017-04-10 AU AU2017248121A patent/AU2017248121B2/en active Active
- 2017-04-10 JP JP2018552775A patent/JP7204484B2/en active Active
- 2017-04-10 KR KR1020187032157A patent/KR20190065189A/en not_active Application Discontinuation
- 2017-04-10 BR BR112018070637A patent/BR112018070637A2/en not_active Application Discontinuation
- 2017-04-10 SG SG11201808750PA patent/SG11201808750PA/en unknown
- 2017-04-10 RU RU2018138837A patent/RU2018138837A/en unknown
- 2017-04-10 ES ES17716871T patent/ES2788188T5/en active Active
- 2017-04-10 WO PCT/EP2017/058578 patent/WO2017174823A1/en active Application Filing
- 2017-04-10 CN CN201780031701.3A patent/CN109476724B/en active Active
- 2017-04-10 CA CA3020555A patent/CA3020555A1/en active Pending
- 2017-04-10 EP EP20020115.0A patent/EP3925972A1/en active Pending
- 2017-04-10 CN CN202310214446.3A patent/CN116239669A/en active Pending
- 2017-04-10 EP EP17716871.3A patent/EP3440104B2/en active Active
- 2017-04-10 MX MX2018012268A patent/MX2018012268A/en unknown
-
2018
- 2018-10-04 IL IL262124A patent/IL262124A/en unknown
- 2018-10-08 US US16/154,270 patent/US20190144521A1/en not_active Abandoned
- 2018-10-15 ZA ZA2018/06862A patent/ZA201806862B/en unknown
-
2021
- 2021-10-14 US US17/501,200 patent/US11753456B2/en active Active
-
2022
- 2022-05-24 JP JP2022084419A patent/JP7572399B2/en active Active
- 2022-10-20 AU AU2022256182A patent/AU2022256182A1/en active Pending
-
2023
- 2023-08-01 US US18/363,672 patent/US20240010702A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019516356A (en) | 2019-06-20 |
| WO2017174823A4 (en) | 2017-12-07 |
| AU2017248121B2 (en) | 2022-07-21 |
| RU2018138837A (en) | 2020-05-12 |
| JP7572399B2 (en) | 2024-10-23 |
| JP2022122913A (en) | 2022-08-23 |
| EP3925972A1 (en) | 2021-12-22 |
| US20220025013A1 (en) | 2022-01-27 |
| JP7204484B2 (en) | 2023-01-16 |
| ZA201806862B (en) | 2021-04-28 |
| ES2788188T3 (en) | 2020-10-20 |
| ES2788188T5 (en) | 2023-10-24 |
| CN109476724A (en) | 2019-03-15 |
| WO2017174823A1 (en) | 2017-10-12 |
| IL262124A (en) | 2018-11-29 |
| US20240010702A1 (en) | 2024-01-11 |
| EP3440104B1 (en) | 2020-03-11 |
| CA3020555A1 (en) | 2017-10-12 |
| US20190144521A1 (en) | 2019-05-16 |
| AU2017248121A1 (en) | 2018-11-22 |
| CN109476724B (en) | 2023-04-04 |
| KR20190065189A (en) | 2019-06-11 |
| US11753456B2 (en) | 2023-09-12 |
| MX2018012268A (en) | 2019-02-07 |
| CN116239669A (en) | 2023-06-09 |
| EP3440104A1 (en) | 2019-02-13 |
| EP3440104B2 (en) | 2023-06-14 |
| RU2018138837A3 (en) | 2020-07-30 |
| BR112018070637A2 (en) | 2019-02-05 |
| AU2022256182A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808750PA (en) | T cell receptors | |
| SG11201808709VA (en) | T cell receptors | |
| SG11201808751SA (en) | T cell receptors | |
| SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808797XA (en) | T cell receptors | |
| SG11201810179RA (en) | Novel crispr enzymes and systems | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
| SG11201909353VA (en) | Hbv vaccine | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201808457PA (en) | Icos ligand variant immunomodulatory proteins and uses thereof | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences |